Two of the most effective treatments for patients with NET (i.e., SSAs and peptide radionuclide therapy) depend on the expression of SSTR2 and SSTR5 on the tumor cell surface [1,4], and these SSTRs are crucial therapeutic targets for SSAs and peptide radioreceptor therapy in NET treatment. Here, SSTR5 is linked to neoplasm.